NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW, "Traws", the "Company"))) today announced it has granted equity awards to new employees who joined Traws in connection with the recent acquisition of Trawsfynydd Therapeutics, Inc. by Onconova Therapeutics, Inc. (the "Merger"). On April 1, 2024, Traws granted restricted stock equity awards to Werner Cautreels, Iain Dukes, Nikolay Savchuk, C. David Pauza and Robert Redfield, as an inducement for each of them to accept employment, which equity awards relate to, 200,000, 67,500, 67,500, 97,500 and 97,500 shares of Traws common stock. One-quarter (1/4) of the shares subject to each restricted stock equity awar

Closing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey PinesFunding expected to advance development of three potential best-in-class/class leading assets: viroksavir, a cap-dependent endonuclease inhibitor for influenza; travaltrelvir, a protease inhibitor for COVID19; and narazaciclib, a next generation CDK4/6 inhibitor for low grade endometriod endometrial cancer (LGEEC)Multiple near-term catalysts, for viroksavir and travaltrevir in 2024, with first top-line read-outs expected in H2 2024Traws Pharma to be led by incoming CEO, Werner Cautreels, Ph.D. Combined board to be led by Executive Chairman Iain Dukes DPhil (OrbiMed) alo

NEWTOWN, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will present an abstract related to preclinical studies conducted by the Company and its collaborators to further characterize the mechanism of rigosertib at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA. "The ability to impact multiple targets is an important characteristic of Onconova's two lead clinical programs, rigosertib and naraz

Preclinical data show that narazaciclib treatment led to significant tumor growth inhibition, demonstrating synergy with standard-of-care ibrutinib, in ibrutinib-sensitive and -resistant settings Early Phase 1/2 studies suggest potential for an improved profile and daily dosing Dose escalation is underway in lead indication of Low Grade Endometrioid Endometrial Carcinoma (LGEEC), with plans to define the Recommended Phase 2 Dose (RP2D) and prepare for registrational studies, with a planned update in H1 2024 NEWTOWN, Pa., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focu

Differentiated profile of narazaciclib supported by positive results of studies demonstrating broad multi-kinase activity, with significant anti-tumor activity and increased anti-tumor immunity, compared to approved CDK4/6 inhibitors Data support the potential use of narazaciclib in breast and ovarian cancers Narazaciclib progressing towards RP2D and preparation for registrational studies, with a planned update in H1 2024 NEWTOWN, Pa., Dec. 08, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced preclin

NEWTOWN, Pa., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova", the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President & CEO, will present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference, being held December 3-5, 2023 at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL. Presentation Details Date/Time:Monday, December 4, 2023, 10:30 AM ET followed by a Breakout SessionSpeaker:Steven Fruchtman, M.D., President & CEO1X1 meetings:The Onconova Managem

Narazaciclib progressing towards registrational studies; target engagement and acceptable safety profile support further dose escalation, affirming differentiated profile Update on the registrational preparations for the narazaciclib program and the rigosertib trial plan expected in the first half of 2024 Company to host conference call and webcast at 4:30 p.m. ET on Tuesday, November 14, 2023 NEWTOWN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today reported third quarter 2023 financial results a

NEWTOWN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its third quarter 2023 financial results on Tuesday, November 14, 2023. Management plans to host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss these results and provide an update on its pipeline programs. Conference Call and Webcast Information Interested parties who wish to participate in the conference call may do so by dialing: (800) 715-9871 for domestic or(646

Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models NEWTOWN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Onconova and collaborators will present a preclinical poster related to its lead program, narazaciclib, at the 65th American Society for Hematology Annual Meeting & Exposition (ASH), taking place in San Diego, California from December 9 to 12, 2023. "The poster that we

Dr. Victor Moyo named Chief Medical OfficerMeena Arora joins as Vice President Global Medical Affairs and R&D NEWTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova", the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company expanded its leadership team with the naming of Dr. Victor Moyo as Chief Medical Officer (CMO), and the addition of Meena Arora as Vice President, Global Medical Affairs and Research and Development (R&D). "We are delighted to have Dr. Moyo and Ms. Arora as integral members of our team at Onconova as we prepar

Dr. Victor Moyo named Chief Medical OfficerMeena Arora joins as Vice President Global Medical Affairs and R&D NEWTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova", the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company expanded its leadership team with the naming of Dr. Victor Moyo as Chief Medical Officer (CMO), and the addition of Meena Arora as Vice President, Global Medical Affairs and Research and Development (R&D). "We are delighted to have Dr. Moyo and Ms. Arora as integral members of our team at Onconova as we prepar

NEWTOWN, Pa., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the appointments of Peter Atadja, Ph.D., and Trafford Clarke, Ph.D., as independent members of the Company's Board of Directors. "It is my pleasure to welcome Peter and Trafford to our Board," said Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova. "Their track record of successfully building and leading teams tasked with the discovery, development, and delivery of novel therapies is impressive. I look forward to benefiti

NEWTOWN, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Dr. Adar Makovski Silverstein has joined Onconova as Director, Corporate Development. "Adar's deep scientific expertise in oncology and business development experience at leading biotechnology companies, most recently at Amgen, make her an excellent addition to our team at Onconova," said Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova. "We are thrilled to have her join us and look forward to benefitting from her insights. Her str

NEWTOWN, Pa., June 01, 2021 (GLOBE NEWSWIRE) --  Onconova Therapeutics, Inc. (NASDAQ:ONTX) ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Mark Gelder, M.D. will be joining Onconova as Chief Medical Officer (CMO), effective as of June 14, 2021. "Mark's extensive experience leading clinical oncology programs at all stages of development makes him an ideal fit for Onconova. He will add great depth to our management team," said Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova. "His wide ranging medical and scientific expertise, which notably covers the deve